The reintroduction of miR-143 into synovial sarcoma cells resulted in decreased ERK5 levels, reduced proliferation, and increased apoptosis, highlighting its potential as a therapeutic target [92]. The gene discussed is MAPK7; the disease is synovial sarcoma.